Drugs /

goserelin

Back to Drugs List

Overview

Generic Name(s):
goserelin
Trade Name(s):
Zoladex
NCI Definition [1]:
A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)

Clinical Trials

View Clinical Trials for goserelin

Goserelin has been investigated in 28 clinical trials, of which 24 are open and 4 are closed. Of the trials investigating goserelin, 2 are phase 1 (2 open), 16 are phase 2 (13 open), 1 is phase 2/phase 3 (1 open), and 9 are phase 3 (8 open).

ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for goserelin clinical trials.

Breast carcinoma, prostate adenocarcinoma, and invasive breast carcinoma are the most common diseases being investigated in goserelin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Goserelin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Goserelin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating goserelin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Zoladex, ici 118630, ici-118630, goserelin product, goserelin, goserelin, goserelin preparation (product), goserelin [chemical/ingredient], goserelin (substance), 6-[o-(1,1-dimethylethyl)-d-serine]-10-deglycinamide luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide, goserelin preparation, ici118630, 6-[o-(1,1-dimethylethyl)-d-serine]-10-deglycinamide luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide, luteinizing hormone-releasing factor (pig), 6-(o-(1,1-dimethylethyl)-d-serine)-10-deglycinamide-, 2-(aminocarbonyl)hydrazide, 65807-02-5
Drug Target(s) [2]:
GNRHR
NCIT ID [1]:
C1374
SNOMED ID [1]:
C-78118

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.